Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Pharmacology, Toxicology and Pharmaceutical Science
1
10%
Unknown
4
40%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 July 2025.
All research outputs
#8,916,853
of 30,007,585 outputs
Outputs from Journal of Clinical Oncology
#16,597
of 27,793 outputs
Outputs of similar age
#88,861
of 324,496 outputs
Outputs of similar age from Journal of Clinical Oncology
#457
of 652 outputs
Altmetric has tracked 30,007,585 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 27,793 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.5. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,496 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 652 others from the same source and published within six weeks on either side of this one. This one is in the 29th percentile – i.e., 29% of its contemporaries scored the same or lower than it.
